RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) granted stock options and restricted stock unit awards to two newly hired non-executive employees under its employment inducement plan.
The awards, approved May 4 by the compensation committee of the company’s board, cover a combined 29,760 stock option shares and 22,320 restricted stock units tied to Mineralys common stock.
The grants were issued under the company’s 2025 Employment Inducement Incentive Award Plan and were intended as hiring incentives in accordance with Nasdaq Listing Rule 5635(c)(4), which permits equity awards to attract new employees outside shareholder-approved compensation plans.
The stock options vest over four years, with 25% vesting on May 4, 2027, and the remainder vesting in monthly installments over the following 36 months, subject to continued employment.
The restricted stock units also vest over four years, with 25% vesting annually beginning May 4, 2027.
Mineralys is developing treatments targeting hypertension and related conditions linked to excess aldosterone production, including chronic kidney disease and obstructive sleep apnea.
The company’s lead drug candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor designed to treat uncontrolled hypertension.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.